Tag: Metastatic colorectal cancer

Takeda signs licensing deal for Hutchmed’s fruquintinib outside of China

Raghuram Kadari- January 24, 2023

Takeda Pharmaceutical will acquire an exclusive worldwide license, excluding China, of fruquintinib from Hutchmed (China) and its subsidiary Hutchmed to strengthen its oncology portfolio. Under ... Read More

Seagen gets FDA accelerated approval for tucatinib, trastuzumab combo for colorectal cancer

Raghuram Kadari- January 21, 2023

American biotechnology company Seagen (formerly Seattle Genetics) has received accelerated approval from the US Food and Drug Administration (FDA) for the company’s oral drug Tukysa ... Read More

Array BioPharma Braftovi triple combo for metastatic colorectal cancer secures FDA breakthrough therapy designation

pharmanewsdaily- August 8, 2018

Array BioPharma secured breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for encorafenib (BRAFTOVI), in combination with binimetinib (MEKTOVI) and cetuximab for ... Read More

Vyriad, Merck to launch phase 1 study of immuno oncology drugs Voyager-V1 and avelumab

pharmanewsdaily- July 18, 2018

Vyriad, a US biotech company, has entered into a collaboration with Germany-based Merck to launch a phase 1 trial of their immuno oncology drugs combination ... Read More